Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year;Utilisation de la mitoxantrone dans les formes malignes inaugurales de sclérose en plaques. Étude observationnelle de 30 cas. Évaluations cliniques et IRM à un an

Revue Neurologique

Volumn 164, Issue 12, 2008, Pages 1028-1034

  Ory, S ^a   Debouverie, M ^b   Le Page, E ^a   Pelletier, J ^c   Malikova, I ^c   Gout, O ^d   Roullet, E ^e   Vermersch, P ^f   Edan, G ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c TIMONE HOSPITAL   (France)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^e HÔPITAL TENON   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Immunosuppressive agent; Malignant; Mitoxantrone; Multiple sclerosis

Indexed keywords

MITOXANTRONE; DIAGNOSTIC AGENT; GADOLINIUM; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BRAIN DAMAGE; BRAIN REGION; CLINICAL ARTICLE; COGNITION; DISEASE COURSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; FEMALE; GADOLINIUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59649121664     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2008.04.008     Document Type: Article

References (26)

1. Comi G., Kappos L., Clanet M., Ebers G., Fassas A., Fazekas F., et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. BMT-MS Study Group. J. Neurol. 247 (2000) 376-382
2. Dale R.C., and Branson J.A. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis?. Arch. Dis. Child 90 (2005) 636-639
3. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62 (1997) 112-118
4. Hartung H.P., and Grossman R.I. ADEM: distinct disease or part of the MS spectrum?. Neurology 56 (2001) 1257-1260
5. Hartung H.P., Gonsette R., König N., Kwiecinski H., Guseo A., Morrissey S.P., et al., for the Mitoxantrone In Multiple Sclerosis study group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360 (2002) 2018-2025
6. Keegan M., Pineda A.A., McClelland R.L., Darby C.H., Rodriguez M., and Weinshenker B.G. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58 (2002) 143-146
7. Kepes J.J. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann. Neurol. 33 (1993) 18-27
8. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expended Disability Status Scale (EDSS). Neurology (Cleveland) 33 (1983) 1444-1452
9. Le Page E, Leray E, Brochet B et al. Long-term safety profile of mitoxantrone in a french cohort of 802 multiple sclerosis patients: final report. ECTRIMS-Madrid, abstract multiple sclerosis 2006;12:S211.
10. Le Page E., Leray E., Taurin G., Coustans M., Chaperon J., Morrissey S.P., et al. Mitoxantrone as induction treatment in aggressive relapsing remitting Multiple Sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients. J. Neurol. Neurosurg. Psychiatry 79 (2008) 52-56
11. Lublin F.D., Lavasa M., Viti C., and Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immun. Immunopath. 45 (1987) 122-128
12. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
13. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
14. Mehler M.F., and Rabinowich L. Inflammatory myelinoclastic diffuse sclerosis. Ann. Neurol. 23 (1988) 413-415
15. Mendez M.F., and Pogacar S. Malignant monophasic multiple sclerosis or "Marburg's disease". Neurology 38 (1988) 1153-1155
16. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 58 (2005) 840-846
17. Rodriguez M., Karnes W.E., Bartleson J.D., and Pineda A.A. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 43 (1993) 1100-1104
18. Scolding N. The differential diagnosis of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 71 Suppl. 2 (2001) ii9-ii15
19. Tindall R.S., Walker J.E., Ehle A.L., Near L., Rollins J., and Becker D. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Neurology 32 (1982) 739-743
20. Watson C.M., Davison A.N., Baker D., O'Neill J.K., and Turk J.L. Suppression of demyelinisation by mitoxantrone. Int. J. Immunopharmacol. 13 (1991) 923-930
21. Weinshenker B.G., and Miller D.H. MS: One disease or many?. In: Siva A., Kesselring J., and Thompson A. (Eds). Frontiers in multiple sclerosis (1998), Martin Dunitz, Ltd, London
22. Weinshenker B.G., O'Brien P.C., Petterson T.M., Noseworthy J.H., Lucchinetti C.F., Dodick D.W., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46 (1999) 878-886
23. Weinshenker B.G., and Rodriguez M. Treatment of catastrophic multiple sclerosis. In: McDonald W.I., and Noseworthy J. (Eds). Multiple Sclerosis 2 (Blue Book Series) (2001), Butterworth-Heinemann
24. Weinstock-Guttman B., Kinkel R.P., Cohen J.A., Ransohoff R.M., Schwetz K., Gogol D., et al. Treatment of fulminant multiple sclerosis with intraveinous cyclophosphamide. The Neurologist 3 (1997) 178-185
25. Weinstock-Guttman B., Ramanathan M., Lincoff N., Napoli S.Q., Sharma J., Feichter J., et al. Study of Mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63 (2006) 957-963
26. Wiertlewski S., Pelletier J., Malikova I., Suchet L., Lebrun C., Vermersch P., et al., on behalf of the CF-SEP (Club Francophone de la Sclérose en Plaques). Clinical presentation and outcome of tumor-like multiple sclerosis: a cohort of 76 patients. AAN Miami P05 (2005) 103